Home LiteratureArticle Details
PMID: 8684209 Published · ppublish English Comment Letter

Tumour marker levels during marimastat therapy.

Lancet (London, England) ·Vol. 348 ·No. 9022 ·1996-07-27 ·Pages 263-4

Gore M, A'Hern R, Stankiewicz M, Slevin M

Abstract

暂无摘要

MeSH Terms
CA-125 Antigen/blood,drug effects Enzyme Inhibitors/pharmacology Female Humans Hydroxamic Acids Metalloendopeptidases/antagonists & inhibitors Ovarian Neoplasms/blood Retrospective Studies
Chemicals
CA-125 Antigen Enzyme Inhibitors Hydroxamic Acids marimastat Metalloendopeptidases
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Gore M
A'Hern R
Stankiewicz M
Slevin M
Article Info
Journal
Lancet (London, England)
Abbr.
Lancet
ISSN
0140-6736
DOI
10.1016/s0140-6736(96)24030-9
Published
1996-07-27
Pages
263-4
Language
English
Region
England
NLM ID
2985213R
Subset
IM
Corrections
CommentOn
PMID: 8684093
External Links
PubMed source DOI: 10.1016/s0140-6736(96)24030-9 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2